Iambic Therapeutics

iambic.ai →

-48%

est. 2Y upside i

HealthcareSeries C

Iambic Therapeutics tackles challenging design problems in drug discovery with its physics-based AI platform.

Rank

#1717

Sector

AI-driven Drug Discovery

Est. Liquidity

~3Y

Data Quality

Data: Medium

Iambic Therapeutics presents a strong upside opportunity driven by its cutting-edge AI platform, promising clinical pipeline, and a significant partnership with Takeda potentially worth over $1.7 billion.

Last updated: March 10, 2026

Bull (25%)+200%

Successful clinical trials for IAM1363 and other pipeline assets, coupled with the Takeda partnership exceeding $1.7B in milestones, drives revenue to $200M+ by 2028. This validates the AI platform and justifies a $4.5B valuation (3x current), attracting further strategic partnerships or an IPO.

Base (45%)+50%

Iambic successfully advances IAM1363 through Phase 2, secures modest additional partnerships, and grows revenue to $75M by 2028. The company maintains its competitive moat but faces ongoing competition, leading to a $2.25B valuation (1.5x current) at a potential acquisition.

Bear (30%)-50%

Clinical trial setbacks or increased competition from large pharma (e.g., Takeda's internal AI efforts) slow pipeline progress and limit new partnerships. Revenue growth stalls at $30M, leading to a down round or acquisition at $750M (0.5x current), significantly eroding common stock value due to $306M in liquidation preferences.

Est. time to liquidity~3.0 years

Preference Stack Risk

high

Investors hold $306M in liquidation preferences ahead of common stock. In an exit at or below the estimated $1.5B valuation, common shareholders would see their returns significantly reduced after these preferences are paid out.

Dilution Risk

high

As a clinical-stage company with very high capital intensity, Iambic will likely require significant additional funding rounds, leading to further dilution for existing shareholders.

Secondary Liquidity

limited

While some secondary market activity exists for accredited investors through platforms like Forge and EquityZen, it is limited and not a reliable source of liquidity for employees.

Questions to Ask at the Interview

Strategic questions based on Iambic Therapeutics's data — designed to show you've done your homework.

  • 1

    “Given the high incumbent threat from large pharmaceutical companies investing in AI drug discovery, how does Iambic plan to differentiate and maintain its competitive edge beyond its current partnerships?”

  • 2

    “With IAM1363 in Phase 1/1b and other programs entering the clinic, what are the key milestones and timelines for advancing your pipeline, and how will these impact revenue growth beyond the current ~$20M?”

  • 3

    “Considering the Series C funding and the recent $50M Series B extension, how does the company envision its path to a liquidity event (IPO or acquisition) for employees, and what is the expected timeline?”

Community

Valuation Sentiment

Our model estimates -48% upside. What do you think?

Anonymous. Do not share material non-public information.

Community Discussion

Comments are reviewed before they appear publicly.

0/2000

Loading comments...

Disclaimer: This analysis is AI-generated and does not constitute financial or career advice. Always conduct your own due diligence.